DocWire News Editors

DocwireNews

In part 3 of Docwire News&rsquo; roundtable series discussing Relapsed/Refractory Multiple Myeloma, moderator Dr. Saad Usmani and Dr. Malin Hultcrantz discuss data from the DREAMM-9 study on a quadruplet combination treatment regimen. Specifically, they discuss how a lower dosing and less frequent schedule for older patients is doable.&nbsp;Saad Usmani: Malin, I want to turn to you and hear about belantamab mafodotin. There was a lot of data, combination data with lower dosing, different schedules being presented in the relapse space in the GSI combinations, the work that you&rsquo;ve done at MSK.I mean, bela is even in the frontline setting. We saw the Len/Dex combo data or the earlier setting data from the Greek Myeloma Group. And then I had the privilege of presenting the early look in the DREAMM 9 study with bela-maf along with IBD for transplant ineligible patients. So, a lot of bela data, but what&rsquo;s your summary?Malin Hultcrantz: The summary is that I think this is a good drug and, since there&rsquo;s a lot of trials going on, obviously it&rsquo;s a good drug, but it has the toxicity with the keratopathy and the ocular toxicity. So there are a lot of efforts trying to mitigate these side effects and doing smart combination and with lower doses, to try to maximize the effect and minimize the side effects. So I think that&rsquo;s what the main takeaway from all of this.I think combining with GSI is something that we&rsquo;re going to start up a trial early next year as well. So that&rsquo;s a gamma secretase inhibitor that inhibits the gamma secretase which sheds BCMA from the cell surface. I think this is a very interesting combination, and hopefully will show very good effects at lower doses, and there&rsquo;s also fewer side effects. So I think this is a drug that&rsquo;s going to be around, but it need to work a little bit more on where exactly to have it and what the best combination is and the best dosing to avoid the ocular toxicity.Saad Usmani: No, I agree. I think even in the DREAMM 9 study, the idea of combining belantamab mafodotin in lower doses and less frequent schedule for older patients. Apparently, the data that was shared shows that it&rsquo;s doable; It&rsquo;s just that we need a longer follow up for those patients. Once you get to that optimal response and multi-mechanism of action approach, you can pare down therapy. So this can be similar to a quad being utilized for X number of cycles, you get to get certain response, and then you go to maintenance.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Relapsed Multiple Myeloma: The DREAMM Trial

Videos

In part 3 of Docwire News’ roundtable series discussing Relapsed/Refractory Multiple Myeloma, moderator Dr. Saad Usmani and Dr. Malin Hultcrantz discuss data from the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe